智通财经APP获悉,7月9日,维泰瑞隆宣布与诺华制药(NVS.US)达成一项战略协议,授予诺华一项独家选择权,以收购其专有的“脑部递送模组(BrainDeliveryModule,BDM)”平台。BDM平台是一种差异化的血脑屏障穿透技术,旨在提高多种形式药物的脑部递送效率。同时,维泰瑞隆保留使用该平台继续开发选定项目的权利。根据协议条款,诺华将在选择权期限内对BDM平台进行评估。若行使选择权,诺华将获得该平台的全球独家权利。维泰瑞隆有资格获得总计高达1.75亿美元的预付款及近期付款。
据悉,维泰瑞隆由王晓东院士和张志远博士在2017年联合创立,是一家处于临床阶段的生物科技公司。该公司致力于开发能够从根本上治疗衰老相关疾病的突破性疗法,聚焦衰老相关疾病的关键致病机理,包括细胞程序性死亡、炎症、能量稳态失衡。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.